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Abstract: The pathogenesis of sporadic Parkinson’s disease (PD) remains enigmatic. Mitochondrial complex-I defects are 
known to occur in the substantia nigra (SN) of PD patients and are also debated in some extracerebral tissues. Early se-
quencing efforts of the mitochondrial DNA (mtDNA) did not reveal specific mutations, but a long lasting discussion was 
devoted to the issue of randomly distributed low level point mutations, caused by oxidative stress. However, a potential 
functional impact remained a matter of speculation, since heteroplasmy (mutational load) at any base position analyzed, 
remained far below the relevant functional threshold. A clearly age-dependent increase of the ‘common mtDNA deletion’ 
had been demonstrated in most brain regions by several authors since 1992. However, heteroplasmy did hardly exceed 1% 
of total mtDNA. It became necessary to exploit PCR techniques, which were able to detect any deletion in a few micro-
dissected dopaminergic neurons of the SN. In 2006, two groups published biochemically relevant loads of somatic 
mtDNA deletions in these neurons. They seem to accumulate to relevant levels in the SN dopaminergic neurons of aged 
individuals in general, but faster in those developing PD. It is reasonable to assume that this accumulation causes mito-
chondrial dysfunction of the SN, although it cannot be taken as a final proof for an early pathogenetic role of this dysfunc-
tion. Recent studies demonstrate a distribution of deletion breakpoints, which does not differ between PD, aging and clas-
sical mitochondrial disorders, suggesting a common, but yet unknown mechanism.  
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1. INTRODUCTION 
  Parkinson’s disease (PD), originally described by the 
physician James Parkinson in 1817, is the second most 
common age-related neurodegenerative disorder after Alz-
heinmer’s disease. The central pathological feature is a pro-
found loss of melanin-rich dopaminergic neurons in the sub-
stantia nigra (SN) pars compacta, which may exceed one half 
of the total neuronal population even at the beginning of 
symptoms. Since these neurons form the nigrostriatal path-
way, which delivers dopaminergic input to the striatum, the 
severe loss of the neurotransmitter dopamine explains the 
central neurological symptoms of PD. Any disease causing 
striatal dopamine deficiency or striatal damage may elicit 
parkinsonism, characterized by tremor at rest, slow volontary 
movements, rigidity and poor balance, PD being the most 
common cause of parkinsonism (around 80% of cases). 
About 95% of PD cases are sporadic and the primary cause 
of neuronal death in the SN is not known. Only the small 
remainder is inherited and some monogenic forms can be 
explained by mutations of a handful of genes involved in 
protein folding, proteasome function, mitochondrial function 
and oxidative stress (reviewed in [1]). Although some of the 
encoded proteins are found in mitochondria or are associated 
with mitochondrial functions, it seems premature to declare 
any unifying hypothesis for common mitochondrial path-
ways in these genetic diseases. This will not be the subject of 
the present review.  
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  Uncertainty of early pathogenetic events in the vast ma-
jority of sporadic PD cases inhibits the development of tar-
geted therapies. Although L-dopa, a dopamin precursor ap-
plied for well established dopamine substitution therapy, can 
help most PD patients, its long term usage often causes the 
appearance of uncontrolled movements (dyskinesias), which 
severely affect the quality of life. It would thus be an intrigu-
ing challenge to uncover the early events of dopaminergic 
cell death at the molecular level. Although the discussion of 
PD is mainly focused on the central feature of dopaminergic 
cell loss in the SN, it should not be forgotten, that the pa-
thology exceeds the nigrostriatal axis by far (for review see 
[2]). Neurodegeneration and Lewy bodies, characteristic 
proteineous inclusion bodies consisting of misfolded -
synuclein and various other misfolded proteins, are not re-
stricted to the SN. They are also observable in noradrenergic, 
serotonergic and cholinergic systems, and occur in some 
areas of the cerebral cortex. Hippocampal neurodegeneration 
may contribute to late dementia in PD patients. This broader 
pathology should be kept in mind, even when weighing the 
latest exciting results obtained from the analysis of single 
dopaminergic SN neurons in human brains.  
2. DYSFUNCTION OF THE ELECTRON TRANS-
PORT CHAIN IN PARKINSON’S DESEASE 
  Besides a basic role of protein misfolding, altered protea-
somal degradation and cellular deposition of these proteins 
in the form of inclusion bodies (Lewy bodies), two other 
main hypotheses of nigral neurodegeneration focus on mito-
chondrial dysfunction and oxidative stress [1, 3, 4]. Since the 
mitochondrial electron transport chain (ETC) complexes I 
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and mitochondrial enzymes are sensitive targets of ROS at-
tacks, these latter two hypotheses are tightly linked. One 
route, by which ETC dysfunction, and mainly complex I 
inhibition, early became implicated in the pathogenesis of 
sporadic PD, was the observation that the intake of MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) contami-
nated preparations of the street drug meperidine can cause a 
parkinsonian syndrome in humans, which is quite similar to 
PD [5]. A similar parkinsonism could also be elicited by 
MPTP in non-human primates, although the African green 
monkey was the only one, in which resting tremor was ob-
served. A product of MPTP metabolism in dopaminergic 
neurons (MPP+) directly inhibits complex I predominantly 
in these cells [6]. Meanwhile, MPTP and the well-known 
complex I inhibitor rotenone, were exploited to establish 
rather artificial, but widely accepted toxic PD models in ro-
dents [7-9]. Complex I inhibitors can even induce deposition 
of Lewy bodies [10] and thus link them as downstream 
events to a mitochondrial pathogenesis.  
  Shortly after the discovery of the parkinsonism inducing 
properties of MPTP, several reports in the late 1980’s and 
early 1990’s detected a moderately decreased activity of 
complex I and sometimes of other ETC complexes in the SN 
and in extracerebral tissues of human patients suffering from 
sporadic PD. Schapira and colleagues [11] analyzed ho-
mogenates of autoptic SN material from nine PD patients 
and nine controls matched with respect to age and post mor-
tem delay. They found rotenone sensitive NADH-CoQ-
oxidoreductase activity (complex I) to be decreased roughly 
by one third in the PD group and confirmed the result by a 
similar decrease in the ratio of rotenone sensitive NADH-
cytochrome c-reductase versus succinate-cytochrome c-
reductase. Normalization of complex I activity to the mito-
chondrial matrix enzyme citrate synthase (CS), which is 
meanwhile routinely used in studies of ETC function, would 
not have changed the results, since CS activity was nearly 
identical in PD and control groups. Succinate-cytochrome c-
reductase activity did not differ between the groups, indicat-
ing no complex II defect in PD. In addition to these results, 
other authors observed a selective decline of some complex I 
polypeptides, but not of subunits of complexes III and IV, by 
immunoblotting [12]. Moderately decreased activities of 
complex I and other ETC enzymes in extracerebral tissues, 
such as skeletal muscle biopsies [13, 14] and platelets [15, 
16] were also described in the early studies, suggesting a 
more widespread and generalized ETC dysfunction in spo-
radic PD, which may just elicit the strongest response in SN 
dopaminergic neurons due to their specific vulnerability. The 
technical problems, such as post mortem delay in SN studies, 
and the surprising extracerebral results initiated a controver-
sial discussion [17]. The results obtained with muscle biop-
sies or blood platelets excluded at least the possibly con-
founding effects of post mortem delay. An ETC suppressing 
influence of L-Dopa treatment itself in the PD groups was 
excluded in studies analysing blood samples of PD patients, 
who were previously untreated with L-Dopa [16]. Inconsis-
tent results obtained with respect to the presence or absence 
of ETC defects in extracerebral tissues and with respect the 
complexes involved, may have been caused by the use of 
classical enzyme measurements, which might not always 
detect moderate ETC dysfunction. More sophisticated tech-
niques, such as inhibitor titrations, may be required [18] and 
were applied in later studies of skeletal muscle and cultured 
skin fibroblasts [19]. In the study of Wiedemann and col-
leagues [19], a moderate, but significant 30% reduction of 
NADH-cytochrome-reductase activity in skeletal muscle 
homogenates of PD patients was observed only after nor-
malization to the significantly increased CS activity. CS in-
crease itself may be interpreted in terms of compensative 
mitochondrial proliferation in skeletal muscle tissue, which 
is well known from classical mitochondrial disorders. In 
mitochondrial disorders, CS normalization of ETC enzyme 
activities is an accepted and established diagnostic proce-
dure. No significant changes in CS normalized activities of 
ETC complexes II + III and IV were observed in PD pateints 
with direct enzyme measurements in muscle homogenates. 
Inhibitor titrations with amytal (complex I) and azide (com-
plex IV) were then performed in saponin-permeabilized 
muscle fiber bundles, in order to determine the gradual inhi-
bition of maximal respiration by increasing inhibitor oncen-
trations and to calculate flux control coefficients for the two 
complexes [18], i.e. their impact on electron flow through 
the ETC. This technique not only confirmed a complex I 
dysfunction, but detected a combined dysfunction of com-
plexes I and IV in the majority of samples. Significantly in-
creased flux control coefficients were also observed for both 
complexes in digitonin-permeabilized skin fibroblasts of PD 
patients, indicating ETC dysfunction in these cells. Mito-
chondrial defects could be restored in half of the analyzed 
skin fibroblast samples by 5 M coenzyme Q [20]. The 
beneficial effects of coenzyme Q (CoQ) underline at least a 
participation of mitochondrial dysfunction at some stage of 
PD pathogenesis.  
  A further line of evidence implicating mitochondria and 
actually the mitochondrial genome (mtDNA) in PD patho-
genesis, comes from ‘cybrid’ studies. While most polypep-
tides of all ETC complexes are transcribed from chromoso-
mal genes, 13 of them are encoded in the small circular 16.6 
kb mtDNA molecule, located in several copies within the 
mitochondrial matrix. This genome contains seven subunits 
of complex I and at least one subunit of all other ETC en-
zymes (with the exception of complex II) and of the mito-
chondrial ATP synthetase. Mitochondrial genes exhibit a 
much higher mutation rate as compared to nuclear genes and 
mtDNA is not protected by histones and exposed directly to 
ROS species generated during respiration. It was thus specu-
lated that oxidative damage to mitochondrial DNA and re-
sulting mutations may play a role for mitochondrial dysfunc-
tion in PD. So called ‘cybrid cells’ (cytoplasmic hybrids) 
were generated to uncouple potential effects of a damaged 
mtDNA from confounding effects of the nuclear back-
ground. In these cells, mtDNA of a tumor cell line (recipient) 
has been replaced by that one of a donor cell, derived from 
either a PD patient or a control. This goal is achieved by 
culturing the recipient cellline in subtoxic concentrations of 
an agent, which depletes the cells of their endogenous 
mtDNA, such as ethidium bromide or rhodamine-6-G. These 
so called rho-zero cells are then fused by polyethylene glycol 
treatment to either blood platelets of the donor (no nucleus) 
or to enucleated fibroblasts. In this way series of cell clones 
can be generated with identical nuclear background, but dif-
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leagues demonstrated moderately decreased complex I activ-
ity (-20%), enhanced ROS production and enhanced MPTP 
sensitivity of neuroblastoma-derived cybrids, containing 
mtDNA from PD platelets [21]. Since only mtDNA was de-
rived from the donor platelets in these experiments, they 
were interpreted as a hint for mtDNA transmission of the 
mitochondrial defect. These results were confirmed by the 
group of Schapira. These authors detected in addition a com-
bined dysfunction of the two analyzed complexes I and IV in 
some of the cybrid clones [22]. In agreement with a dis-
turbed mitochondrial function, lower ATP content and depo-
larized mitochondria were observed in teratoma-derived PD 
cybrids, together with higher LDH (lactate dehydrogenase) 
release and caspase-3 activity under unstimulated conditions, 
indicating enhanced cell death [23]. Even -synuclein oli-
gomerization, as a potential step towards Lewy body forma-
tion, could be defined as an mtDNA-transmissable down-
stream effect of mitochondrial dysfunction in PD cybrids. A 
more detailed discussion of the cybrid model can be found in 
the review of Trimmer and Benett [24].  
  Despite these hints for mtDNA transmission of mito-
chondrial dysfunction, direct sequencing of mtDNA from PD 
patients revealed no homoplasmic or heteroplasmic muta-
tions, which were associated with the disease. This circum-
stamce fed the speculation that randomly distributed, somatic 
mutations may occur at low heteroplasmy levels (mutational 
loads), undetectable by direct sequencing. The mutations 
were thought to be caused by ROS (reactive oxygen species) 
generated in the ETC, a process which may be enhanced in 
dopaminergic neurons of the SN due to additional ROS 
sources in their metabolism.  
3. OXIDATIVE STRESS AND OXIDATIVE DNA 
DAMAGE  
  While oxidative stress is commonly accepted to occur in 
the SN of PD patients, its pathogenetic impact remains un-
certain. It may just accompany a late stage of cellular degen-
eration as an unspecific feature of dying neurons, or it may 
reflect or actually elicit mitochondrial dysfunction at a rela-
tively early time, when the decision of an individual cell’s 
fate is being made. In the latter scenario, it would be worth 
to test pharmacological interventions, capable of restoring 
ETC function and scavenging ROS. A theoretically promis-
ing molecule for this purpose is the flexible electron carrier 
and antioxidant ubiquinone (coenzyme Q10, CoQ10). While it 
indeed protects primary dopaminergic neurons in vitro 
against MPTP induced cell death [25] and seems to partially 
restore complex I function in tissues of PD patients [26], the 
results of clinical trials, assessing neuroprotection, have been 
contradictory. Some small-sized studies found beneficial 
effects in UPDRS scores (Unified Parkinson Disease Rating 
Scale) or visual symptoms [27-29], but benefitial effects 
were not generally confirmed in all studies [30]. Although 
neuroprotective efficacy of antioxidative treatments in hu-
mans may be questionable, the fact of oxidative changes in 
lipids, proteins and nucleic acids in the SN of PD patients 
has been confirmed by many investigators (for review see 
[4]).  
  Malonaldehyde, a marker of lipid peroxidation, was 
found to be increased, while the total amount of polyunsatu-
rated fatty acids was decreased [31]. The compound 4-
hydroxy-2-nonenal, which is interpreted as a product of the 
peroxidation of membrane-bound arachidonic acid in the SN 
of PD patients, was shown to built protein adducts [32], 
which also occur in -synuclein and alter its aggregation 
properties [33]. This peroxidation product may thus support 
Lewy body formation, a morphological hallmark of PD. 
Carbonyl modifications of soluble proteins are also increased 
in PD [34, 35], as well as nitration and nitrosylation of pro-
teins, including -synuclein [36]. Protein carbonyls of com-
plex I subunits were enhanced in brain mitochondria from 
PD patients [37], indicating oxidative damage of this com-
plex itself, which may partially explain the reduced activity. 
On the level of DNA, the marker 8-hydroxy(deoxy) 
guanosine (8-OHdG/8-OHG) demonstrates the enhanced 
oxidative damage in the SN of PD brains [34, 38]. It is of 
interest, that the increase of this oxidation product in the SN 
of human PD patients was rather selective (Fig. 1), while no 
significant changes were observed in other oxidation– or 
deamination products [34]. The base modification 8-OHG is 
not a result of direct reactions of DNA with superoxide or 
hydrogen peroxide [39-41], which are liberated as the pri-
mary ROS species during electron transport and superoxide 
dismutase (SOD2) reaction, respectively. Hydroxyl radicals, 
generated in the presence of ferrous iron by the Fenton reac-
tion, can hydroxylate DNA bases, but would have been ex-
pected to generate a broader spectrum of oxidation products 
in PD. Since this broader increase was not observed, the pre-
cise mechanism of enhanced oxidative DNA damage re-
mained uncertain.  
  Oxidative stress markers have been meanwhile described 
by several studies even in extracerebral tissues and bodily 
fluids of PD patients [38, 42-45], including an increase of 8-
OHdG/ 8-OHG in the cerebrospinal fluid [46, 47]. This 
points towards a more generalized oxidative stress affecting 
and probably mutating nuclear and mitochondrial DNA.  
  Besides the possible pathogenetic impact of oxidative 
stress in the dopaminergic neurons, a second important ques-
tion cannot be answered sufficiently at present: the origin(s) 
of oxidative stress. Is it mainly caused by enhanced ROS 
production of inhibited ETC complex I or by enhanced ROS 
generation from other metabolic sources, such as dopamine 
metabolism? Or may it be caused by a lowered antioxidative 
defense, allowing higher ROS concentrations even under 
conditions of unaltered production? Is the primary patho-
genic role of complex I in the dopaminergic neurons that one 
of an important ROS source or of an important ROS target? 
What comes first: ETC damage or oxidative stress?  
  One early biochemical alteration observed in the SN of 
PD patients, a loss of reduced glutathione (GSH), may sup-
port an important role of weakened antioxidative defense 
[48, 49]. In the dopaminergic celllines PC12 and N27, com-
plex I inhibition was provoked as a secondary event follow-
ing experimental GSH depletion [50, 51]. This suggests that 
complex I dysfunction in the SN of PD brains may rely on or 
at least be enhanced by GSH depletion. On the other hand, it 
has been suggested that chronic mild complex I inhibition 
may reduce the concentration of the antioxidant GSH by 
enhanced ROS production. The first ROS species generated 
by complexes I and III, superoxide, is metabolized to hydro-588    Current Genomics, 2009, Vol. 10, No. 8  E. Kirches 
gen peroxide by manganese-dependent superoxide dismutase 
(SOD2) in the mitochondrial matrix. Hydrogen peroxide is 
partially detoxified by glutathione peroxidase in a GSH con-
suming reaction. Disturbed ETC function and oxidative 
stress may be tightly linked and enhance each other.  
  If ETC dysfunction and oxidative stress occur also at 
extracerebral sites in PD, as suggested by several reports, 
why do mainly dopaminergic neurons die? One important 
factor to explain selective vulnerability of the dopaminergic 
cell population, is the relatively high baseline of ROS pro-
duction due to dopamine (DA) metabolism. Both, enzymatic 
DA degradation by monoamine oxidase and intracellular 
autooxidation of DA yield H2O2 [52, 53], while the latter 
process in addition generates superoxide and a reactive DA-
quinone [54, 55]. The DA-quinone in turn may directly par-
ticipate in nucleophilic addition reactions with sulfhydryl 
groups, thus damaging neuronal proteins and supporting 
GSH depletion [56, 57]. Reactive quinones and semiqui-
nones can be built in addition during cyclooxygenase-2 cata-
lyzed reactions of DA [58].  
  Since ROS generation in the ETC may induce mtDNA 
mutations, which in turn may inhibit ETC complexes and 
enhance mitochondrial ROS production, a long debate dealt 
with a possible ‘vicious cycle’, which may lead to a self-
accelerating feedback between oxidative DNA damage and 
mutagenesis, leading to an accelerated (non-linear) accumu-
lation of mutated mtDNA in aging dopaminergic neurons. 
Since accumulation of such mutations, widely distributed 
over the mitochondrial genome, offered an attractive expla-
nation for the age-dependent onset and progressive worsen-
ing of PD and some other neurodegenerative diseases, 
mtDNA came into the focus of research.  
4. HETEROPLASMIC POINT MUTATIONS OF LOW 
ABUNDANCE 
  In the 1990s some sequenced mtDNA mutations, i.e. in-
herited homoplasmic or heteroplasmic mutations represent-
ing a relatively high percentage of total mtDNA, had been 
suspected to be more frequent in Caucasian PD patients as 
compared to haplogroup-matched controls (belonging to the 
same branch of the mtDNA evolutionary tree). However, 
studies with larger numbers of well characterized or pathol-
ogically proven PD cases could not confirm any of these 
predicted PD associated mtDNA mutations [59, 60], reject-
ing the idea of a maternally inherited mtDNA contribution to 
complex I dysfunction. Even more sophisticated approaches, 
designed to detect heteroplasmic mtDNA contributions be-
tween 5 and 10% in two complex I genes, did not yield any 
significant differences between PD and control groups in 
DNA isolated from SN or platelets [61].  
  However, these results did not exclude a higher burden of 
widely distributed heteroplasmic mutations in PD tissues, 
which may reach only extremely low heteroplamy levels at 
any given base position and thus require highly sensitive 
detection techniques. Such mutations of low abundance 
would actually be expected, if somatic mutagenesis was 
driven by oxidative stress. PCR-cloning of mtDNA with a 
proofreading polymerase and subsequent sequencing of 
clones is a technique, which allows to further enhance the 
sensitivity of mutation detection. It is mainly limited by the 
endogenous error rate of the chosen proofreading polymerase 
and by the fussiness of this rather time-consuming method. 
Due to the latter circumstance, the method usually allows 
only small sample sizes, and results must be interpreted with 
caution. A few studies used this technique to analyze various 
tissues of PD patients and age-matched controls. In their first 
study, Smigrodski and colleagues compared all seven com-
plex I genes of the mtDNA in six PD patients versus six age-
matched controls [62]. The authors used autoptic frontal cor-
tex tissue, since they had previously found frontal cortex to 
manifest the complex I defect and suggested a strong dilu-
tion of mutated DNA in tissue homogenates of the SN, due 
to the severe loss of dopaminergic neurons in the end stage 
disease, represented in autoptic brain tissue. Indeed, this ar-
gument applies to the early biochemical studies too (see 
above), which detected only moderate complex I dysfunction 
in the SN. By sequencing a mean of 94.4 clones of every 
complex I region per case, the authors were able to achieve a 
sensitivity of roughly 1% heteroplasmic DNA. Although 
they did not detect a significant difference in the total muta-












Fig. (1). Among various DNA adducts quantified in the study of Alam and colleagues [34], selectively 8-OHG exhibited a pronounced and 
significant increase in the SN of 10 PD patients (filled circles) as compared to the SN of 10 aged-matched controls (open circles). The distri-
butions of the determined concentrations (normalized to mg DNA) did not even overlap between the groups. Modified according to [34]. Do mtDNA Mutations Participate in the Pathogenesis  Current Genomics, 2009, Vol. 10, No. 8    589 
in a few codons of five subunits were restricted to PD sam-
ples, suggesting disease-specifity. Due to the low number of 
tissue samples, a retrospective narrowing of the viewpoint 
like this, includes the risk of selecting artificial differences 
rather than identifying possible hot spots of somatic muta-
tions in PD. Most of the selected codons exhibited a muta-
tion frequency just above the detection limit, i.e. one muta-
tion in all seqnenced clones. Nevertheless, the authors ana-
lyzed a small candidate region between codons 120 and 150 
of the ND5 subunit in more detail in a second study [63]. 
This study included frontal lobe brain tissue from eight idio-
pathic PD patients and eight controls. Methods used were 
identical to the first study, but analysis was restricted to the 
ND5 gene. Fifteen out of 16 samples could be correctly as-
signed to the two groups on the basis of mutation data, since 
the mutations in the selected region (ND5, codon 124–148) 
were restricted to the PD group with the exception of one 
control. This result suggested that a selective target region 
for low abundance mtDNA mutations in idiopathic PD might 
have been identified. Again it should be emphasized that all 
but one of the observed mutations occurred at a hetero-
plasmy level just above the detection limit of the assay.  
  Stimulated by these results, our laboratory analyzed with 
a similar cloning technique skeletal muscle from five idio-
pathic PD cases of the akinetic-rigid type, which had suf-
fered from PD between two and thirteen years, and had pre-
viously been shown to exhibit a complex I dysfunction in a 
skeletal muscle sample, a small frozen part of which was 
now used for DNA preparation [64]. The mean percentage of 
mutated clones was 2.1% in PD versus 2.7% in age-matched 
controls. The exclusion of silent mutations shiftet the per-
centages to 1.7% versus 1.9%, indicating no increase in PD. 
The results were roughly in accordance with the overall mu-
tation frequencies observed in the frontal cortex tissue by 
Smigrodski and colleagues [62], but did not reproduce the 
ND5 region between codons 120 and 150 as a hotspot for 
low abundance mutations in complex I deficient PD tissue. 
The highest frequency of mutated clones (6.1%) was actually 
observed in a control sample without any known history of 
neurodegenerative or neuromuscular disorder. Although the 
difference between the studies may reflect the different tis-
sue sources, it is unlikely that low abundance ND5 mutations 
generally play a major role in complex I defects outside the 
SN.  
  Another study used the so called ‘double PCR and diges-
tion (DPD)’ method to measure specific base exchanges in 
mildly ETC deficient skeletal muscle of nine PD cases and 
nineteen controls at two specific positions of the mtDNA (np 
7445 and 8993). Both base substitutions are known to be 
pathogenic due to their proven role in classical mitochondrial 
disorders, but both sites are located outside of complex I 
genes, i.e. in subunits of cytochrome c oxidase and ATP-
synthetase. The method was originally used to investigate 
mtDNA point mutations in aging muscles [65] and had been 
used to demonstrate mutations of low abundance in spinal 
cords of patients with another neurodegenerative disease, i.e. 
amyotrophic lateral sclerosis [66]. The method exploits a 
step of endonuclease digest to destroy most wild type PCR 
products, in order to enrich the low abundant mutations, 
prior to a second PCR step and quantification of the bands. 
The method revealed a slight, but significant increase of the 
two selected mutations in PD muscles [67]. Altogether, stud-
ies concerning low abundant point mutations analyzed in 
homogenates of various PD tissues, delivered conflicting 
results.  
5. RELEVANT LOADS OF MITOCHONDRIAL DNA 
DELETIONS IN AGING DOPAMINERGIC NEURONS  
5.1. Age-Dependent Increase of the Common Deletion in 
Brain Homogenates 
  Aging is the main risk factor for developing idiopathic 
PD. Another type of mtDNA mutation of low abundance in 
the human brain had been clearly associated since the year 
1992 with the process of aging: the so called ‘5 kb common 
deletion’. Using dilution-PCR, Corral-Debrinski and co-
workers demonstrated that this large scale deletion accumu-
lates dramatically in the putamen of aged persons, but to a 
lesser extend also in occipital, frontal and temporal cerebral 
cortex, while the cerebellum was largely devoid of deleted 
mtDNA [68]. A similar heterogeneity was reported in the 
same volume of ‘Nature Genetics’ by Soong and colleagues, 
who observed a dramatic age-dependent accumulation of the 
deletion in SN, caudate nucleus and putamen and a much 
smaller increase in various other brain regions, including 
parietal and frontal cortex, globus pallidus, hippocampus, 
centrum semiovale and thalamus [69]. Again, the lowest 
levels were measured in the cerebellar grey matter. A few 
later studies largely confirmed this aged-dependend increase 
of the ‘common deletion’ in the human brain, including un-
published observations in our laboratory obtained by Real-
Time-PCR. The deletion affects several genes of complexes 
I and IV and of the ATP-synthetase, as well as several 
tRNAs needed for translation of mitochondrial transcripts. If 
the mutational load reaches a functional threshold, it be-
comes clearly pathogenic as underlined by some classical 
mitochondrial disorders. In these disorders (chronic progres-
sive external ophthalmoplegia, Kearns-Sayre-syndrome), the 
‘5 kb common deletion’ and other large scale rearrangements 
can be usually found at high levels in skeletal muscle tissue. 
In contrast, the deletion burden in aging human brains seems 
to be usually below 1% of total mtDNA, although the quanti-
tative estimations in such PCR-studies differed in detail. 
However, there is no doubt that even the highest reported 
heteroplasmy levels were far below the threshold expected to 
cause a significant decline of ETC enzyme activities, which 
was estimated to be around 60% [70]. A functional impact of 
deletions in age-dependent neurodegeneration may be con-
sidered, if various clonally expanding deletions accumulate 
in the same brain region, the measured ‘common deletion’ 
being just the tip of the iceberg. Alternatively and more 
likely, a true functional impact of deletions may simply be 
masked in tissue homogenates, if a high mutational burden is 
restricted to a specific cell population. Although the mecha-
nism for the accumulation of deletions remains unclear, oxi-
dative stress in metabolically active brain regions was sug-
gested to play a role. It is interesting to stress the high con-
tent of dopaminergic neurons in the most severely affected 
regions: SN, caudate nucleus and putamen. Considering this 
situation, it was necessary to develop PCR-techniques to 
analyze the mitochondrial genome of single dopaminergic 
neurons, derived from PD patients or elderly individuals 
without neurodegenerative disease.  590    Current Genomics, 2009, Vol. 10, No. 8  E. Kirches 
5.2. Functional Levels of Clonal Deletions in Microdis-
sected Dopaminergic Neurons  
  Fourteen years after the initial studies described above, a 
major breakthrough was achieved independently by two 
groups in the year 2006, who demonstrated the age-
dependent accumulation of clonal somatic mtDNA deletions 
in individual nigral neurons, which reached relevant levels to 
cause ETC dysfunction and eventually neuronal death. 
  Bender and colleagues [71] examined a cohort of indi- 
viduals suffering from PD, who had a history of movement  
disorder and prominent dementia, as well as widespread   
Lewy body formation. Most important, some of these indi- 
viduals exhibited a less pronounced neuronal loss in SN, a  
situation which is considered to be favourable for mtDNA  
studies. The authors first established a histochemical method  
for the detection of ETC deficient neurons, based on a dou- 
ble staining for ECT enzymes cytochrome c oxidase (COX)  
and succcinate dehydrogenase (SDH). This technique is well  
established to detect COX deficient muscle fibers in classical  
mitochondrial disorders. It is a good surrogate marker for   
cells with deletions or other severe mutations of the mtDNA,  
which affect multiple ETC complexes. Since no SDH   
subunit is encoded by the mitochondrial genome, SDH coun- 
terstain yields bright blue cells in case of COX deficiency,  
which is of special advantage in melanin containing   
brownish neurons. A significantly greater proportion of   
COX-negative neurons occurred in the SN of PD brains as  
compared to age-matched controls. Sequencing of the whole  
mitochondrial genome, amplified from nine individual COX- 
negative neurons of PD patients, revealed no relevant point  
mutations explaining COX deficiency, such as base ex- 
changes in tRNAs or in conserved COX codons. The low   
impact of point mutations in individual neurons was later   
confirmed by a separate study of the same group [72]. Next,  
the authors pooled 50 laser-microdissected neurons from   
frozen SN. Long-range PCR, designed to detect all large- 
scale deletions irrespective of their localisation within the   
genome, detected only mtDNA with deletions (mtDNA) in  
PD patients and age-matched controls. This suggested a high  
percentage of mtDNA copies, although long-range PCR is  
not quantitative and certainly favours shorter templates. At  
least microdissected glial cells revealed only full length   
products, supporting the reliability of the method. Applying  
the same technique to single microdissected neurons, multi- 
ple large-scale deletions of different length were found in   
individual cells (Fig. 2). This result must be interpreted in  
terms of a clonal expansion within the individual cells, most  
likely reflecting somatic mutations. Clonality was confirmed  
by sequencing of four deletion breakpoints.  
  To allow reliable quantification of mtDNA, the authors 
took advantage of the fact that nearly all deletions of the 
mitochondrial genome occur in one half of the circular mole-
cule. This allowed a relative PCR-quantification of two short 
fragments, representing either the deletion-prone major arc 
of mtDNA (complex I gene ND4) or the commonly unaf-
fected half of the molecule (ND1). Twenty-five microdis-
sected nigral neurons with normal COX activity from PD 
patients were compared with age-matched controls. High 
levels of the mutations were observed, which seemed to be 
somewhat higher in PD patients (mean value 52.3%) as 
compared to controls (43.3%), although the difference was 
not significant (p = 0.06). These mean levels were near to the 
suggested functional threshold around 60%, which was ex-
ceeded in some cells. Moreover, the mean level of deletions 
was significantly higher in COX-negative cells as compared 
with COX-positive neurons, underlining the functional im-
pact. The formerly described age-dependency of deletion 
burden in the brain [68, 69] was confirmed in microdissected 
nigral neurons. The same PCR assay from hippocampal neu-
rons did not reveal such relevant mutational burden. 
  Largely the same results with respect to aging and func-
tional COX decline were obtained in an independent study of 
Kraytsberg and colleagues, who analyzed brains of individu-
als between 33 years and 102 years of age with similar 
methods [73]. The study was published in the same volume 
of ‘Nature Genetics’. In many of the microdissected dopa-
minergic nigral neurons, the percentage of mtDNA ex-
ceeded the suggested threshould of 60%. This was the case 
in a large fraction of neurons for individuals above their 
eigth decade of life (Fig. 3), a feature which corresponds 
nicely to age-dependent PD risk. In several other neuronal 
cell types, such as pyramidal cells of the cortex, cerebellar 
Purkinje cells and large neurons of the dentate nucleus, 
mtDNA was usually undetectable. A detailed analysis in a 
single 80-year old individual with a high percentage of 
COX-negative nigral neurons revealed that these cells usu-
ally exhibited a mutational burden above 60%, while COX-
positive neurons did not. Another recent analysis of micro-
dissected neurons in aged individuals and Alzheimer patients 
revealed that the mutational load in the SN generally ex-
ceeded that one in frontal cortex, but also in dopaminergic 
neurons of the putamen [74]. Disease status played no role.  
  Taken together, the reports clearly established a connec-
tion between progressive mitochondrial genome deletion 
during aging and developing ETC dysfunction in the SN, 













Fig. (2). Gel showing results of single-cell PCR detection of vari-
ous clonal large-scale deletions between 1 and more than 8 kb in 
size, which occurred in single COX-positive or COX-negative do-
paminergic neurons of the SN of a 75-year old subject, modified 
according to [71]. M = 1 kb ladder, C = control muscle representing 
the fragment length generated from intact mtDNA.  Do mtDNA Mutations Participate in the Pathogenesis  Current Genomics, 2009, Vol. 10, No. 8    591 
gion. They deliver exiting hints, but do not demonstrate une-
quivocally that this process of deletion-driven mitochondrial 
dysfunction is accelerated in PD patients.  
6. POSSIBLE ORIGINS OF CLONAL DELETIONS 
AND THEIR POSSIBLE ROLE IN PARKINSON’S 
DISEASE 
  The nature of mitochondrial DNA deletions in nigral 
neurons still remains unclear. A comparison of breakpoints 
was performed in laser-microdissected individual neurons of 
brains from PD patients, aged individuals and one patient 
suffering from autosomal progressive external ophthalmo-
plegia (PEO) due to mutations in the polymerase- (POLG) 
gene. Polymerase- copies the mitochondrial genome. Muta-
tions of this gene in autosomal PEO cause a fragility of 
mtDNA, which leads to multiple mtDNA-species e.g. in 
skeletal muscle of the patients. Moreover, the disease is 
sometimes associated with parkinsonism. In all groups, most 
deletions (mean value 79%) were flanked by perfect or im-
perfect short direct repeats, suggesting a common mecha-
nism [75], irrespective of the disease scenario. Based on an 
early model of mammalian mtDNA replication [76], dele-
tions had been originally discussed to occur during replica-
tion by slipped mispairing between direct repeats [77, 78]. 
Even in the light of novel modified models [79] the replica-
tion process remains a hypothetical source of large-scale 
deletions. Alternatively, they could be generated by recom-
bination during repair of damaged DNA [80]. Since dopa-
minergic neurons of the SN are exposed to enhanced ROS 
levels and reactive quinones, oxidative stress is hypothesized 
to play a role. It may either impair replication or induce 
DNA repair mechanisms, which favour rearrangements. The 
latter hypothesis is supported by experiments showing that 
artificially generated double strand breaks (DSBs) induce 
large-scale deletions in mice [81, 82]. Double strand breaks 
can result from stalling of the replication fork, but also from 
oxidative stress, offering a hypothetical link to dopaminergic 
metabolism.  
  The elegant mouse model, recently developed by the 
group of C. Moraes, allowed to generate DSBs in the mouse 
brains in a timely and spatially controlled manner and to 
observe accumulation of mtDNA-species and functional 
defects over time [82]. The authors expressed a mitochon-
dria-targeted gene for the restriction endonuclease PstI in the 
brains, which was controlled by a Tet-promoter. This ap-
proach simulated naturally occurring DSBs in the mitochon-
drial genome, if mice were grown in the absence of doxoru-
bicin (Dox). In this case mice developed a neurodegenerative 
‘limb-clasping’ phenotype, which was suppressed in mice 
grown with Dox within the first three weeks of life. Only 
continuously Dox treated mice reached a normal lifespan. As 
expected, expression of the restriction enzyme reduced the 
ratio of intact mitochondrial DNA versus nuclear DNA in 
striatum, hippocampus and cortex and induced a decline of a 
catalytic COX subunit and of COX activity. The authors 
detected many large-scale deletions of mtDNA, although 
smaller ones (longer PCR products) were expected to be 
missed by the technique. A closer characterization of these 
DSB-induced deletions revealed that 59% of them contained 
no direct repeats and were thus more likely to be generated 
by non-homologous end-joining than by homologous recom-
bination involving repeats. Even after timely limited PstI 
expression, the brains continued to accumulate mtDNA, 
suggesting clonal expansion. This elegant model supports the 
hypothesis that both, repeat-free and repeat-bearing deletions 
may be caused by unknown oxidative damage-induced repair 
mechanisms, while replication errors may contribute to the 
latter type.  
  Despite the exciting progress made possible by sophisti-
cated single-cell PCR techniques and mouse models in the 
last three years, important questions arising from those stud-
ies cannot be answered at present. Currently, one of the most 
important of these unresolved questions is: what may drive a 
slightly faster accumulation of mtDNA in a minority of 
individuals, who are then condemned to develop full-blown 
PD? May a short incidental increase in oxidative stress and 
DSBs (e.g. by environmental noxes) be sufficient to initiate a 
fatal process of mtDNA accumulation, leading to ETC dys-
function and finally neuronal death? What makes the differ-
ence between PD and normal aging?  
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